Oramed snags Israeli government grant for insulin pill; FDA clears Providence cervical delivery implant;

> Israeli oral insulin company Oramed ($ORMP) pulled in a government grant from the Office of the Chief Scientist for $265,000 to support R&D and clinical studies for its insulin pill ORMD-0801. Release

> Providence Medical Technology snagged 510(k) clearance for its PMT Cervical Cage, a minimally invasive implant and drug-delivery platform for cervical fusion procedures. Release

> Depomed ($DEPO) received a complete response letter from the FDA saying the agency would not approve the application for the company's investigational oral menopause treatment SEFELSA, and Depomed will no longer continue to invest in it. Release

> Genoa Pharmaceuticals worked with researchers at McMaster University to demonstrate that an inhaled treatment for pulmonary fibrosis works better in vivo than oral therapy. Release

> BD Medical launched its BD Neopak, a glass prefillable syringe system that eliminates glass-to-glass contact, resulting in fewer visual defects and increased glass strength, and has reduced silicone levels. Item

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.